12/2
12:08 pm
rhhby
Roche (OTCMKTS:RHHBY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Roche (OTCMKTS:RHHBY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
12/2
01:15 am
rhhby
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis) [Yahoo! Finance]
Low
Report
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis) [Yahoo! Finance]
12/1
09:22 am
rhhby
Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/1
09:00 am
rhhby
Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium
Low
Report
Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium
12/1
04:36 am
rhhby
Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials [Seeking Alpha]
Low
Report
Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials [Seeking Alpha]
11/29
06:25 am
rhhby
Roche Holding (SWX:ROG): Evaluating Valuation Following Recent Share Price Rally [Yahoo! Finance]
Low
Report
Roche Holding (SWX:ROG): Evaluating Valuation Following Recent Share Price Rally [Yahoo! Finance]
11/20
03:23 am
rhhby
Is Flatiron Health Integration Expanding Natera's Market Opportunity and Investment Narrative for NTRA? [Yahoo! Finance]
Low
Report
Is Flatiron Health Integration Expanding Natera's Market Opportunity and Investment Narrative for NTRA? [Yahoo! Finance]
11/19
01:38 pm
rhhby
How the Narrative Around Roche Is Evolving Amid Analyst Updates and Clinical Shifts [Yahoo! Finance]
Low
Report
How the Narrative Around Roche Is Evolving Amid Analyst Updates and Clinical Shifts [Yahoo! Finance]
11/19
08:53 am
rhhby
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors [Yahoo! Finance]
Low
Report
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors [Yahoo! Finance]
11/19
01:48 am
rhhby
European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma [Yahoo! Finance]
Low
Report
European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma [Yahoo! Finance]
11/18
01:29 am
rhhby
Genentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer [Yahoo! Finance]
High
Report
Genentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer [Yahoo! Finance]
11/18
01:10 am
rhhby
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
High
Report
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
11/17
01:42 pm
rhhby
Henlius and Organon score first US Perjeta biosimilar approval [Yahoo! Finance]
Low
Report
Henlius and Organon score first US Perjeta biosimilar approval [Yahoo! Finance]
11/17
08:12 am
rhhby
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
Low
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
11/15
07:05 pm
rhhby
Roche Holding (SWX:ROG): Examining Valuation After Recent Share Price Momentum [Yahoo! Finance]
High
Report
Roche Holding (SWX:ROG): Examining Valuation After Recent Share Price Momentum [Yahoo! Finance]
11/13
02:03 pm
rhhby
Roche's breast cancer drug Perjeta faces copycats as FDA approves first biosimilar [Seeking Alpha]
Low
Report
Roche's breast cancer drug Perjeta faces copycats as FDA approves first biosimilar [Seeking Alpha]
11/13
01:17 am
rhhby
Zealand Pharma Announces Financial Results for the First Nine Months of 2025 [Yahoo! Finance]
High
Report
Zealand Pharma Announces Financial Results for the First Nine Months of 2025 [Yahoo! Finance]
11/12
01:00 am
rhhby
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
Low
Report
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
11/11
09:21 am
rhhby
DeepScribe's Oncology Momentum Accelerates: Ambient AI Set to Capture 3.1 Million Cancer Care Visits Annually [Yahoo! Finance]
Low
Report
DeepScribe's Oncology Momentum Accelerates: Ambient AI Set to Capture 3.1 Million Cancer Care Visits Annually [Yahoo! Finance]
11/11
07:03 am
rhhby
Roche (OTCMKTS:RHHBY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.
Medium
Report
Roche (OTCMKTS:RHHBY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.
11/10
10:28 am
rhhby
Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions [Globe and Mail, The (Toronto, Canada)]
Low
Report
Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions [Globe and Mail, The (Toronto, Canada)]
11/10
10:11 am
rhhby
Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions [Yahoo! Finance]
Low
Report
Geneseeq Receives NMPA Approval for PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions [Yahoo! Finance]
11/10
01:11 am
rhhby
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis [Yahoo! Finance]
Medium
Report
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis [Yahoo! Finance]
11/10
01:10 am
rhhby
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Medium
Report
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
11/7
06:34 pm
rhhby
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up [Yahoo! Finance]
Medium
Report
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up [Yahoo! Finance]